Navigation Links
PAREXEL Consulting Enhances European Regulatory Affairs Capabilities With Appointment of Medical Products Agency Expert Dr. Anders Neil

BOSTON, Feb. 17 /PRNewswire-FirstCall/ -- PAREXEL Consulting, a business unit of PAREXEL International (Nasdaq: PRXL) and leading global consultancy serving the biopharmaceutical and medical device industries, has appointed Anders Neil, Ph.D., to the position of Principal Consultant in its European Product Development Practice. Dr. Neil, former Senior Expert, Pharmacology and Toxicology, at Sweden's Medical Products Agency (MPA), will advise clients on all aspects of clinical development and regulatory affairs. He joins the PAREXEL Consulting team of global experts, which includes former regulatory officials and biopharmaceutical industry professionals, focused on helping companies manage risk and maximize product and portfolio value at every milestone and during each phase of development.

With more than 20 years of experience, Mr. Neil's background includes pharmacology research, drug discovery, and drug development. Prior to working at the MPA, Dr. Neil's career included more than 10 years in the pharmaceutical industry, serving as Principal Scientist at Biovitrum AB as well as Group Manager, Pharmacology at Kabi-Pharmacia/Pharmacia & Upjohn.

"We expect clients will benefit greatly from the insight Dr. Neil has gained from helping to shape regulatory policies in Europe," said Peter Lassoff, Pharm D, Vice President, Europe, PAREXEL Consulting. "Dr. Neil's scientific advice and extensive regulatory and clinical experience will be invaluable in many areas, including in understanding new pediatric requirements as well as applying proactive safety strategies and risk management methodologies. He also brings a wealth of expertise in regard to product development in Sweden, which is the fourth largest biopharmaceutical market in Europe, to supplement our industry leading capabilities in Scandinavia."

"PAREXEL's consulting experts are recognized for managing successful interactions with regulatory agencies, delivering world-class submissions, and helping biopharmaceutical companies define and execute the most efficient paths to approval," said Dr. Neil. "I am proud to join such a high caliber team of experts to help clients with scientific decisions, especially early in development planning, and with regulatory approaches to achieve first-cycle approval."

Dr. Neil was appointed as Senior Expert by MPA in 2005, following his long-term role as MPA Team Leader. During his tenure at MPA Dr. Neil assessed marketing authorizations and clinical trial applications, including nonclinical and pharmacology aspects of more than 1,000 applications spanning all stages of development and therapeutic areas. He has served as an expert to the European Committee for Proprietary Medicinal Products (CPMP), now the Committee for Medicinal Products for Human Use (CHMP), and to its Safety Working Party as a rapporteur on European Union (EU) regulatory documents. Dr. Neil was also appointed to the EU Commission's list of scientific experts on emerging and newly identified health risks. Dr. Neil is currently an Associate Professor of Pharmacology at Uppsala University in Sweden.

For more information about PAREXEL Consulting's full capabilities and areas of expertise, visit:

About PAREXEL Consulting

PAREXEL Consulting, a division of PAREXEL International, provides integrated product development services with the goal of helping biopharmaceutical and medical device companies get their products to the market, and keep them on the market. Through a unique fusion of scientific, regulatory, and business expertise PAREXEL Consulting helps clients worldwide manage risk and maximize product and portfolio value at every milestone and during each phase of development.

About PAREXEL International

PAREXEL International Corporation is a leading global biopharmaceutical services organization, providing a broad range of knowledge-based contract research, medical communications and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 71 locations throughout 51 countries around the world, and has over 9,250 employees. For more information about PAREXEL International visit

This release contains "forward-looking" statements regarding future results and events. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "intends," "appears," "estimates," "projects," "targets," and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business, including, but not limited to, the successful business integration and anticipated synergy achievements in connection with the ClinPhone acquisition; the impact on the Company's business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2008 as filed with the SEC on November 7, 2008, which "Risk Factors" discussion is incorporated by reference in this press release. The forward-looking statements included in this press release represent the Company's estimates as of the date of this release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release.

PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc. or their respective owners and are hereby acknowledged.

    Jennifer Baird, Senior Director of Public Relations
    PAREXEL International
    Tel: +781-434-4409

    Rebecca Passo
    SHIFT Communications
    Tel: +617-779-1817

SOURCE PAREXEL International Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. PAREXEL Reports Second Quarter Fiscal Year 2009 Financial Results
2. PAREXEL Announces Date of Second Quarter Fiscal Year 2009 Earnings Release and Conference Call
3. PAREXEL Reports Preliminary Second Quarter Results
4. PAREXEL International to Present at NASDAQ OMX 22nd Investor Program
5. PAREXEL Reports First Quarter Fiscal Year 2009 Financial Results
6. PAREXEL International to Present at Robert W. Bairds 2008 Growth Stock Conference
7. PAREXEL International to Present at Bank of America 2008 Smid Cap Conference
8. Third-Party Audits: EHA Consulting Group Releases Comments on Food Safety Consultant Auditors' Qualifications and Competencies
9. Best Practice Database adds Research Highlighting the Value of Internal Consulting and Early-Stage Commercialization Groups in the Pharmaceutical Industry
10. New Study Provides Benchmarks for Best Practices for Valuing Internal Consulting Organizations
11. Brent McKenzie Joins ARMSRx Pharmacy Benefit Consulting
Post Your Comments:
(Date:11/25/2015)... ... November 25, 2015 , ... Dental professionals who would like to ... are invited to attend Dr. Mark Iacobelli’s Advanced Implant Mentoring (AIM) CE course. Courses ... , As the co-founders of Advanced Implant Mentoring (AIM), Dr. Iacobelli and Dr. ...
(Date:11/25/2015)... ... 2015 , ... The McHenry County law firm of Botto Gilbert Lancaster, ... Francisco J. Botto and Alex C. Wimmer. Attorneys Botto and Wimmer represented the claimant ... (2d) 130884WC. , According to court documents, Adcock testified that on May 10, 2010 ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... board certified facial plastic surgeon specializing in both surgical and non-surgical treatments, announced ... Skin Spa at Hobgood Facial Plastic Surgery. , Highly trained and nationally ...
(Date:11/25/2015)... ... November 25, 2015 , ... In an ongoing Clinical Study conducted by ... Chicago, IL, UV Angel is evaluating the efficacy of its product and its disinfection ... (totaling 30 beds) from May 2014 through October 2015 at a 360-bed, acute-care, academic ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... provide scholarships for people struggling with eating disorders as a result of the ... second annual event, held at Fox Run Golf Club in Eureka, will help ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... -- 3D bioprinting market is expected to ... report by Grand View Research Inc. Rising prevalence of chronic ... transplantation is expected to boost the market growth, as 3D ... --> 3D bioprinting market is expected to ... report by Grand View Research Inc. Rising prevalence of chronic ...
(Date:11/26/2015)... 2015 Research and Markets ( ... "2016 Future Horizons and Growth Strategies in the ... Country Segment Forecasts, Competitive Intelligence, Emerging Opportunities" ... --> --> This new 247-page ... therapeutic drug monitoring market, including emerging tests, technologies, ...
(Date:11/26/2015)... 26, 2015 ... "2016 Future Horizons and Growth Strategies ... Market: Supplier Shares, Country Segment Forecasts, Competitive ... offering. --> ) has ... Future Horizons and Growth Strategies in the ...
Breaking Medicine Technology: